Figure 7. Immunofluorescence staining of the lumbar spinal cord section of SOD1G93A transgenic mouse transplanted with F3.Olig2-Shh cells.
Image credit: Lee, et.al. 2014 under CC BY license

Funding Opportunities

To submit any new grant opportunities for this list, please email ALSgrants@prize4life.org. List the sponsor name, amount, due date, and contact information.

 


 

Current Funding Opportunities:


NEW! Postdoctoral Fellowships
Sponsor: AFM-Telethon
Description: This International Call for Proposals, open to both French and foreign groups, aims to support research which will increase our understanding of the increase our understanding of the neuromuscular system and/or encourage the development of therapies for neuromuscular and rare genetic diseases. Funding is awarded for the first year, renewable for a second year. A maximum of 2620.85 to 3615.13 euros/month will be awarded. Note: Concerning projects on ALS, priority will be given to those with an applicability to SMA.
Deadline: Application due by September 5, 2017.



NEW! Pathfinder III (High Risk High Reward Neurodegenerative Research)
Sponsor: Network of Centres of Excellence in Neurodegeneration (CoEN)
Description: This call sets out to encourage the community to think “outside the box”, to stimulate new and unconventional approaches and creative solutions to the challenges of neurodegeneration research by undertaking high-risk / high-payoff research. Research to be supported include: cutting edge basic, translational and/or clinical studies; novel reductionist systems; innovative disease models; systems biology / medicine; proof of concept for new therapeutic approaches; and supportive technological development. Awards will be typically €115K-€400K for 2 years. But clinical and pre-clinical animal studies up to €660K will also be considered. Research teams must include teams from two or more participating countries: Canada, France, Germany, Italy, Ireland, Spain and the UK.
Deadline: Application due by September 18, 2017.



NEW! High Throughput Screening of Therapeutic Molecules
Sponsor: Fondation Maladies Rares
Description: This funding program supports projects aimed at identifying molecules with potential benefit in the treatment of rare diseases. Projects will be based on a high throughput/ high content screening (HTS/HCS) approach using compound libraries, towards the discovery of active molecules ‘hits’ with therapeutic potential. A second step towards investing into the ‘hit to lead’ process to approach drug-like characteristics will be supported. A maximum of €25,000 will be awarded for assay development and screening, and €25,000 for ‘hit to lead’ process by experimental and in silico approaches. The principal investigator must be based in France.
Deadline: Application due by September 19, 2017.



NEW! Repurposing Existing Experimental and FDA-Approved Drugs
Sponsor: National Center for Advancing Translational Sciences (NCATS)
Description: This funding program supports pre-clinical studies to repurpose existing experimental or FDA approved drugs or biologics (existing therapeutics) that have already begun or completed at least a Phase l trial. The hypothesis for proposed studies must be developed using innovative processes to identify the therapeutic/indication pair. Examples include independent crowdsourcing strategies (e.g., http://www.ncats.nih.gov/ntu/assets/current, http://openinnovation.astrazeneca.com/), or use of computational algorithms. The initial UG3 award will support the development of milestone-driven rigorous, pre-clinical target engagement and/or efficacy studies. Once UG3 pre-clinical milestones have been met, the UH3 award may be made to support clinical trial planning: this includes complete planning, design, and preparation of the documentation necessary for implementation of Phase I and/or Phase II clinical trials for a new therapeutic use.
Deadline: Letter of Intent due by September 30, 2017.



MND Research Grants
Sponsor: MND Australia
Description: Seed-funding for research that is innovative and has a clear relationship to the causes, treatments and cures of MND or the support of people living with MND. Applicants must have Australian permanent residency or be Australian citizens. Funding is up to $100,000 AUD for one year.
Deadline: Application due by August 25, 2017.



Postdoctoral Research Fellowships
Sponsor: MND Australia
Description: Postdoctoral scientists with a track record in areas of neuroscience related to MND and no more than three years postdoctoral research experience. Applicants must have Australian permanent residency or be Australian citizens. Salary for a full-time research fellow will be funded at $100,000 p.a. for a period of up to three years.
Deadline: Application due by August 25, 2017.



The Betty Laidlaw MND Research Prize
Sponsor: MND Australia
Description: The Betty Laidlaw MND Research Prize aims to reward an outstanding mid-career researcher in Australia with a demonstrated background of excellence in neuroscience research. The Prize is for an innovative 12-month project to advance the understanding of classical MND with a clear potential for effective treatments. It aims to support research commencing in the calendar year 2018. Funding is up to $250,000 AUD for one year.
Deadline: Application due by August 25, 2017.



Clinical FTD Research Pilot Grants
Sponsor: Association for FTD (AFTD)
Description: AFTD Clinical Research Pilot Grants provide seed funding for innovative research projects in the preliminary stages of development with the potential to address the unmet medical needs of frontotemporal degeneration (FTD). The FTD disorders include: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS/MND. Applications are welcome from investigators at not-for-profit institutions as well as for-profit organizations. The award is $60,000 USD for one year. Pilot Grant funded projects are intended to generate data to support follow-on grant applications to the National Institutes of Health (NIH) or other public or private agencies.
Deadline: Application due by September 8, 2017.



Pilot Grant for Basic Science FTD Research
Sponsor: The Association for FTD (AFTD)
Description: AFTD Basic Science Pilot Grants provide seed funding for innovative research projects that expand our understanding of the biology or pathophysiology of frontotemporal degeneration (FTD). The FTD disorders include: behavioral variant FTD, primary progressive aphasia, progressive supranuclear palsy, corticobasal syndrome, and FTD-ALS/MND. Applications are welcome from investigators at not-for- profit institutions or biotechnology startup organizations. The award is $60,000 USD for one year. Pilot Grant funded projects are intended to generate data that will support follow-on grant applications to the National Institutes of Health (NIH) or other public or private agencies.
Deadline: Application due by September 8, 2017.



Frick Foundation for ALS Research Award
Sponsor: Bruno and Ilse Frick Foundation for Research on ALS
Description: The aim of the Foundation is to encourage basic biomedical research related to understanding the cause of ALS. The funding is 100,000 CHF over 2 years.
Deadline: Application due by October 6, 2017.



Biomedical Research Project Grants
Sponsor: Motor Neurone Disease Association
Description: The MND Association supports biomedical research on ALS and related conditions, in all relevant disciplines. The objectives of the MND Association research funding programme are to support research aimed at understanding the causes of MND, elucidating disease mechanisms and facilitating the translation of therapeutic strategies from the laboratory to the clinic. Researchers outside the UK are eligible to apply if the project is unique in concept or design (i.e. not being performed in the UK) or the project involves a significant collaboration with a UK institute. Applications for project grants should not exceed £85,000 per annum (and £255,000 in total) without the prior agreement of the MND Association. Applications received beginning September 8, 2017.
Deadline: Application due by November 3, 2017.



ADDF NIH Scored Unfunded Grants (includes FTD)
Sponsor: Alzheimer's Drug Discovery Foundation
Description: This request for proposals supports NIA and NINDS grant proposals in NIH format that were scored but not funded, which fall within our mission and research priorities. This includes frontotemporal dementias.
Deadline: Applications are accepted on a rolling basis..



CLIN 2: Partnering Opportunity for Clinical Trial Stage Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of a clinical trial for a stem cell treatment that addresses an unmet medical need.
Deadline: Last business day of each month.



CLIN 3: Partnering Opportunity for Supplemental Accelerating Activities
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to support new activities on active CIRM-funded development projects that will significantly accelerate development of the proposed treatment or increase the likelihood of success.
Deadline: Last business day of each month.



Catalyst Grant: New Genes for Rare Diseases
Sponsor: Rare Diseases Models and Mechanisms Network
Description: On behalf of the Clinical Advisory Committee of the Rare Diseases: Models and Mechanisms Network, the Co-Chairs would like to invite applications from clinicians and clinician scientists who have discovered novel genes in patients with rare diseases and wish to collaborate with a model organism investigator who is able to carry out functional analysis on an orthologous gene in a model system. A maximum of $25,000 CAD will be awarded. Applications may be submitted by any investigator associated with a Canadian Institution.
Deadline: Applications will be accepted on a rolling basis.



Clin1: Partnering Opportunity for Late Stage Preclinical Projects
Sponsor: California Institute of Regenerative Medicine (CIRM)
Description: The objective of this program announcement is to create a highly competitive partnering opportunity for promising stem cell-based projects to accelerate the completion of preclinical activities necessary to attain an active IND or IDE with the FDA and to initiate start-up activities of the proposed clinical trial. CIRM expects projects under this program to advance rapidly into the clinic and to be accomplished within two years unless adequately justified.
Deadline: Last business day of each month.



Healthcare Research Grants
Sponsor: Motor Neurone Disease Association (MNDA)
Description: MNDA invests in research that fills knowledge gaps in clinical management of MND, adding to the evidence base and driving improvements in quality of care for people affected by MND.  
Deadline: Now accepting applications.



NIH TRND Program and NIH BrIDGs Program
Sponsor: NIH National Center for Advancing Translational Sciences (NCATS)
Description: NCATS is now accepting proposals on a rolling basis to collaborate with Bridging Interventional Development Gaps (BrIDGs) and Therapeutics for Rare and Neglected Diseases (TRND) program scientists. Click here to apply.
Deadline: Now accepting rolling applications.



NINDS Training and Career Development Awards
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description: NINDS offers a wide range of training and career development funding opportunities including pre-doctoral fellowships, post-doctoral fellowships, mentored career development awards, institutional programs, independent scientists awards, clinical research awards and more. All programs are open to researchers focusing on the study of ALS and related conditions.
Deadline: Varies, see individual program for details.



NeuroNEXT Infrastructure Resource Access
Sponsor: NIH National Institute of Neurological Disorders and Stroke (NINDS)
Description:

This funding opportunity announcement (FOA) encourages proposals for biomarker validation trials or exploratory clinical trials of drugs, biologics, surgical therapies or devices that may contribute to the justification for and provide the data required to design a future trial to confirm efficacy (i.e., a Phase III trial) in the treatment of neurologic disease. Proposals for drugs or biologics should provide compelling scientific evidence that the investigational agent proposed for study will reach/act upon the designated target or that its mechanism of action is such that it will be of benefit in ameliorating a specific aspect of the disease.

Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.


Deadline: Now accepting rolling applications.



Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail